25 años de CENTIS. Pandemia y Radiofármacos
Resumen
Palabras clave
Referencias
Nuclear Medicine/Radiopharmaceuticals Market. Nuclear medicine/radiopharmaceuticals market by type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), Application (Oncology, Cardiology) - Global Forecast to 2024. [website]. Available in: https://www.marketsandmarkets.com/Market-Reports/radiopharmaceuticals-market-417. [access: june 20, 2020].
Radiopharmaceuticals Market. 2019 analysis and review of radiopharmaceuticals market by application - oncology, cardiology, gastroenterology, neuroendocrinology, neurology, and nephrology for 2019 - 2029 [website]. Available in: https://www.futuremarketinsights.com/reports/radiopharmaceuticals-market. [access: june june 20, 2020].
Global Radiopharmaceuticals Market - Industry Trends - Forecast to 2026. https://www.databridgemarketresearch.com/reports/global-radiopharmaceuticals-market. [access: june 19, 2020].
National Academies of Sciences, Engineering, and Medicine. Opportunities and approaches for supplying molybdenum-99 and associated medical isotopes to global markets. Proceedings of a Symposium. Washington, DC: The National Academies Press, 2018. https://doi.org/10.17226/24909.
OPS/OMS. Repositorio Institucional para el Intercambio de Información (IRIS). Indicadores básicos 2019. Tendencias de salud en Las Américas [sitio web]. Disponible en: Disponible en: https://iris.paho.org/handle/10665.2/51543 [access: july 28, 2020].
Market Data Forecast. Latin America nuclear medicine radiopharmaceuticals market research report - segmented by diagnostics, by therapeutics, by application, by country (Mexico, Brazil, Argentina, Chile and Rest of Latin America) - Industry Analysis, Size, Share, Growth, Trends, Forecasts (2019-2024) [website]. Available in: https://www.marketdataforecast.com/market-reports/latin-america-nuclear-medicine-radiopharmaceuticals-market. [access: june 25, 2020].
PÁEZ D, ORELLANA P, GUTIÉRREZ C, RAMIREZ R, MUT F. AND TORRES L . Current status of nuclear medicine practice in latin america and the caribbean. J Nucl Med. 2015; 56(10): 1629-1634
HENNRICH U, KOPKA K. Lutathera®: The First FDA- and EMA-Approved radiopharmaceutical for peptide receptor radionuclide therapy. pharmaceuticals (Basel) 2019; 12(3): 114. doi: 10.3390/ph12030114 3390/ph12030114 http://www.mdpi.com/journal/pharmaceuticals. [access: february 15, 2020].
SCHWARZ SW, CLARKE B. Perspective on how the fda should review diagnostic radiopharmaceuticals. J Nucl Med . 2018; 59(6): 865-867.
SCHWARZ SW, DECRISTOFORO C, et. al. Harmonization of U.S., European Union, and Canadian first-in-human regulatory requirements for radiopharmaceuticals: is this possible? J Nucl Med . 2019; 60(2): 158-166. doi: 10.2967/jnumed.118.209460.
SCHWARZ SW, DECRISTOFORO C. US and EU radiopharmaceutical diagnostic and therapeutic nonclinical study requirements for clinical trials authorizations and marketing authorizations. EJNMMI Radiopharmacy and Chemistry. 2019; 4:10. https://doi.org/10.1186/s41181-019-0059-2.
SHARMA N, KAUR H & SHARMA RK. Radiopharmaceuticals regulations: current scenario and the way forward. Applied Clinical Research, Clinical Trials & Regulatory Affairs, 2017; 4: 1-12.
DECRISTOFORO C & LYASHCHENKO SK. Recommendations for conducting clinical trials with radiopharmaceuticals. In: nuclear medicine textbook. August, 2019. https://doi.org/10.1007/978-3-319-95564-3_41.
NEELS O, PATT M & DECRISTOFORO C. Radionuclides: medicinal products or rather starting materials?. EJNMMI Radiopharmacy and Chemistry . 2019; 4: 22. https://doi.org/10.1186/s41181-019-0074-3.
SHARMA S, SANYOG J, et. al. Intricacies in the approval of radiopharmaceuticals - regulatory perspectives and the way forward. Current Science. 2019, 116(1): 47-65. doi: 10.18520/cs/v116/i1/47-55.
U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Oncology therapeutic radiopharmaceuticals: nonclinical studies and labeling recommendations guidance for industry (pharmacology/toxicology). August, 2019.
Food and Drug Administration (FDA). E17 General principles for planning and design of multiregional clinical trials. FDA, 2018. Available at: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM519603.pdf. [access: july 24, 2020].
AuntMinnie.com [website]. https://www.auntminnie.com/index.aspx?sec=dis&ItemID=129109, 129130, 128809, 128819, 128750, 128734, 128865, 129176, 129177, 129073, 129191, 129316, 129345, 129349, 129357 . [access: June, 2020].
MERKEL C, WHICHER CH, BOMANJI J, HERRMANN3 K, et. al. Realising the potential of radioligand therapy: policy solutions for the barriers to implementation across Europe. European Journal of Nuclear Medicine and Molecular Imaging. 2020; 47: 1335-1339 https://doi.org/10.1007/s00259-020-04745-7
PAEZ D, GNANASEGARAN G, FANTI S, et. al. COVID-19 pandemic: guidance for nuclear medicine departments. Eur J Nucl Med Mol Imaging. 2020; 47: 1615-1619. https://doi.org/10.1007/s00259-020-04825-8
HUANG HL, GNANASEGARAN G, PAEZ D, et. al. Nuclear medicine services after COVID-19: gearing up back to normality. Eur J Nucl Med Mol Imaging . 2020; 47: 2048-2053. https://doi.org/10.1007/s00259-020-04848-1.
International Atomic Energy Agency (IAEA). COVID-19 pandemic: technical guidance for nuclear medicine departments. Vienna: IAEA, July 2020. 50 p.
Human Health Campus [website]. https://humanhealth.iaea.org/HHW/ Global Radiopharmaceuticals Market (COVID 19 UPDATE) Overview by Type, Technological Advancements & Forecast to 2027,https://jewishlifenews.com/uncategorized/global-radiopharmaceuticals-market-covid-19-update-overview-by-type-technological-advancements-forecast-to-2027/
Radiopharmaceuticals Market Analysis 2020- Industry Trend, Revenue, Top Players, Size, Share, COVID-19 Impact, Region, Feasibility, Economics, Pricing Analysis, Opportunities, Forecast to 2025. Published: June 12, 2020 https://www.marketwatch.com/press-release/nuclear-medicine-or-radiopharmaceuticals-market-analysis-2020--industry-trend-revenue-top-players-size-share-covid-19-impact-region-feasibility-economics-pricing-analysis-opportunities-forecast-to-2025
BOSCHI A., LICIA UCCELLI L. & MARTINI P. A picture of modern Tc-99m radiopharmaceuticals: production, chemistry, and applications in molecular imaging. Review. Appl. Sci. 2019; 9: 2526-2542. doi: 10.3390/app9122526.
PILLAI MRA, NANABALA R, JOY A, SASIKUMAR A, KNAPP FF. Radiolabeled enzyme inhibitors and binding agents targeting psma: effective theranostic tools for imaging and therapy of prostate cancer. Nucl Med Biol. 2016; 43(11): 692-720 doi: 10.1016/j.nucmedbio.2016.08.006.
LEE WW. Clinical applications of technetium-99m quantitative single-photon emission computed tomography/computed tomography. Nucl Med Mol Imaging . 2019; 53(3): 172-181. doi.org/10.1007/s13139-019-00588-9.
MANTEL I, WILLIAMS J. An introduction to newer PET diagnostic agents and related therapeutic radiopharmaceuticals. J of Nucl. Med. and Technol. 2019; 47(3): 203-209 doi:10.2967/jnmt.118.224022.
SWACHCHHANDA S, PANKAJ N, et. al. Axumin positron emission tomography: novel agent for prostate cancer biochemical recurrence. J Clin Imaging Sci. 2019; 9: 49. doi: 10.25259/JCIS_139_2019.
PETRONI D, MENICHETTI L, POLI M. Historical and radiopharmaceutical relevance of [18F] FDG. Journal of Radioanalytical and Nuclear Chemistry. 2020. https://doi.org/10.1007/s10967-020-07013-y.
SOLNES LB, WERNER RW, JONES KM, SADAGHIANI MS. Theranostics: leveraging molecular imaging and therapy to impact patient management and secure the future of nuclear medicine. J. of Nucl. Med. 2020; 61: 311-318. doi:10.2967/jnumed.118.220665.
KENDI AT, HALFDANARSON TR, PACKARD A, DUNDAR A, SUBRAMANIAM RM. Therapy With 177Lu-DOTATATE: clinical implementation and impact on care of patients with neuroendocrine tumors. Review. Nucl. Med. and Mol. Imaging. 2019; doi.org/10.2214/AJR.19.21123.
ALBERTI RAMÍREZ A, GARCÍA RODRÍGUEZ E, CRUZ ARENCIBIA J, MORÍN ZORRILLA J. Fósforo-32 e Itrio-90 como opciones en el tratamiento del dolor óseo metastásico. Nucleus. 2016; (60): 24-28.
SOWA-STASZCZAK A, et. al. Efficacy and safety of 90Y-DOTATATE, therapy in neuroendocrine tumours. Polish Journal of Endocrinology. 2011; 62: 5.
CWIKLA JB, et. al. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Annals of Oncology. 2010; 21: 787-794.
SCHULTZ WA. Molecular Biology of Human Cancers. Springer Science + Business Media, Inc. 2005.
HICKS RJ, JACKSON P, KONG G, WARE RE, et. al. 64Cu-SARTATE PET Imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy. J Nucl Med . 2019; 60: 777-785. doi: 10.2967/jnumed.118.217745.
ClinicalTrials.gov [website] Identifier: NCT04023331. 67Cu-SARTATE™ peptide receptor radionuclide therapy administered to pediatric patients with high-risk neuroblastoma. https://www.smartpatients.com/trials/NCT04023331 . [access: August, 2020].